- Report ID: BMRC 1371 | Number of pages: 200 | Publish Date: Oct 2020
Status: Published | Category: Chemical And Materials | Delivery Timeline:
Biologics Safety Testing Market is valued at USD 3.48 Billion in 2019 and expected to reach USD 8.44 Billion by 2026 with the CAGR of 13.5% over the forecast period.
Biologics Safety Testing Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2020-2026– Growing number of drug launches and increasing incidences of chronic diseases are some of the major factors driving the growth of Global Biologics Safety Testing Market.
Biologics are the large and complex molecules derived from the genes of living organisms by advanced DNA technologies. These are advanced drugs used in treatment of cancer, rheumatoid arthritis, and other diseases. These biologics are actively incorporated in the development of new medicines as well as improvement of existing drugs. Testing the safety of these biologics is critical for avoiding the inadvertent inclusion of unknown entities in drug manufacturing system. Additionally, biological safety testing is carried by using various tests such as sterility tests, endotoxins test, residual host contamination detection tests, and bioburden tests among others. However, untested and unsafe biologics can cause a greater harm to global population as drugs derived from them can create new abnormalities for patients, and further complicate their health conditions. Moreover, biologics are products derived from biological sources and used as medicines in humans or animals. Biologics can include viruses, substances derived from blood and serum, toxins, antitoxins, vaccines, and large polypeptides.
Global biologics safety testing market report is segmented on the basis of product type, test type, application and region & country level. Based upon product type, global biologics safety testing is classified into kits & reagents, services and instruments. Based upon test type, the market is segmented into endotoxin test, sterility test, cell line authentication and characterization test, bioburden test, residual host contaminant detection test, adventitious agent detection tests and other test. Based upon application, the biological safety testing market segmented in to vaccine & therapeutics development, blood and blood-related product testing, cellular and gene therapy, tissue and tissue-related product testing and stem cell research.
The regions covered in this Biologics safety testing market report are North America, Europe, Asia-Pacific and rest of the World. On the basis of country level, market of biologics safety testing sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Global biologics safety testing report covers prominent player’s Charles River Laboratories International, Inc, Merck KGaA, Lonza Group Ltd., SGS S.A., Thermo Fisher Scientific Inc, Wuxi APPTEC, Sartorius AG, Cytovance Biologics, Inc, Pace Analytical Services Inc, Toxikon Corporation, Eurofins Scientific SE, Avance Biosciences Inc, Source Bioscience and others.
Eurofins Germany Completed its Testing Portfolio for BioPharmaceuticals
October 4, 2018; through the acquisition of PHAST GmbH, Eurofins BioPharma Product Testing Germany strengthened its service portfolio for the research-oriented biotech and pharmaceutical industries by offering full service testing packages for large and small molecules. Customers now benefit from a complete package of physico-chemical and microbiological tests for raw materials, finished products, APIs and excipients.
Increasing Drug Launches, Stringent Government Regulations Regarding Biologics are some of the Factors Driving the Market Growth.
Rise in pharmaceutical and biotechnology industry, huge R&D investment by key players in the life sciences industry, and increase in number of new drug launches in recent years are some of the major factors driving the market growth. Increase in number of new biologics by biotechnology and pharmaceutical manufacturers and increasing base of numerous patients worldwide are also expected to boost the market growth within the forecast period. For example, according to U.S. National Library of Medicine National Institutes of Health; nearly half approximately 45% or 133 million of all Americans suffer from at least one chronic disease. According to the Centers for Disease Control, in the U.S. alone, chronic diseases account for nearly 75 percent of aggregate healthcare spending, or an estimated $5300 per person annually.
However, stringent regulatory requirements and longer approval time may act as a restraining factor for the market. In spite of that, increasing pharmaceutical outsourcing and technological advancement and increase number of applications are may create more opportunities for the further growth of the market.
North America is expected to Dominate the Global Biologics Safety Testing Market
North America is expected to account for the highest market share of the biologics safety testing market and the region is also expected to dominance over the forecast period due to the increasing prevalence of chronic diseases, growing inclination towards the consumption of biologics safety testing in various applications and presence of key players in this region. For example; in 2018; the research and development (R&D) expenditure of its member companies reached USD 79.6 billion worldwide. The pharmaceutical sector invests more money in R&D than many other industries: PhRMA members spent around 19.5 percent of their combined global revenues on R&D in 2018. Europe is the second largest regional market for biologics safety testing owing to the high R&D spending, growing biologics development projects, government support for R&D and presence of developed healthcare infrastructure in this region.
Key Benefits for Global Biologics Safety Testing Market Report-
|Years :||2019||Market Size in 2019:||US$ 3.48 Billion|
|Market Historical Analysis:||2015-2019||Forecast Analysis:||2020-2026|
|Forecast Period CAGR %:||13.5%||Market Size Expected to reach in 2026:||US$ 8.44 Billion|
|Pages:||200||Tables, Charts & Figures:||164|
|Top Companies:||Charles River Laboratories International, Inc, Merck KGaA, Lonza Group Ltd., SGS S.A., Thermo Fisher Scientific Inc, Wuxi APPTEC, Sartorius AG, Cytovance Biologics, Inc, Pace Analytical Services Inc, Toxikon Corporation, Eurofins Scientific SE, Avance Biosciences Inc, Source Bioscience and others.|
|Market Segmentation:||Product Type, Test Type, Application|
|Regional Analysis:||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
By Test Type:
Regional & Country Analysis
The Middle East and Africa
Interested in this report?
Biologics Safety Testing Market Global Size: By Product (Kits & Reagents, Services, Instruments), By Test Type( Endotoxin Test Sterility Test Cell Line Authentication and Characterization Test, Bioburden Test, Residual Host Contaminant Detection Test, Adventitious Agent Detection Tests, ) By Application ( Vaccine & Therapeutics Development, Blood and Blood-Related Product Testing, Cellular and Gene Therapy, Tissue and Tissue-Related Product Testing, Stem Cell Research) Forecast to 2026